Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8
Rhea-AI Summary
Prenetics (NASDAQ: PRE) announced a capital allocation shift to focus exclusively on its consumer health brand IM8. The company ceased daily Bitcoin purchases on Dec 4, 2025 and will not pursue future Bitcoin acquisitions, while retaining its existing 510 BTC as a treasury reserve. Prenetics reported a strong financial position with over $70 million in cash and cash equivalents and zero debt. IM8 reached over $100 million annualized recurring revenue within 11 months of launch, and the company projects FY2026 IM8 revenue of $180–$200 million. Capital will be directed to IM8 growth activities including product innovation, brand building, talent, working capital, and international expansion.
Positive
- IM8 reached $100M ARR in 11 months
- FY2026 IM8 revenue guidance of $180–$200M
- Balance sheet with $70M+ cash and zero debt
- Retains 510 BTC as treasury reserve
Negative
- Company will no longer purchase Bitcoin (ceased Dec 4, 2025), reducing portfolio diversification
- Capital allocation concentrated exclusively on IM8, increasing reliance on one business
Key Figures
Market Reality Check
Peers on Argus 1 Up
Sector peers showed mixed moves, with names like FONR up 26.26% on no news while others were modestly up or down. PRE’s pre-news decline of 3.55% appears stock-specific rather than part of a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Warrant exchange | Positive | -6.9% | Voluntary exchange reduced warrant overhang and simplified capital structure. |
| Nov 25 | Conference participation | Positive | +8.6% | Upcoming investor conferences increased visibility and investor engagement opportunities. |
| Nov 24 | Insider share purchases | Positive | +11.2% | Senior executives bought shares in the open market, signaling confidence. |
| Nov 14 | Analyst rating/target | Positive | -9.4% | Overweight rating and higher target based on strong IM8 metrics and liquidity. |
| Nov 10 | Earnings results | Positive | -3.6% | Record Q3 revenue and robust IM8 KPIs with reaffirmed FY2026 guidance. |
PRE has often seen share-price weakness following generally positive or balance-sheet-strengthening news, indicating a pattern of divergence between fundamentals and short-term reactions.
Over the last few months, Prenetics has focused on strengthening its balance sheet and fueling IM8 growth. Record Q3 2025 results on Nov 10 highlighted rapid IM8 scaling, followed by a positive analyst note on Nov 11. Executives then executed sizable open-market share purchases in mid-November, and the company completed a warrant exchange on Dec 23 to reduce potential dilution. Today’s capital-allocation shift away from daily Bitcoin purchases toward IM8 extends this theme of concentrating resources on the consumer health opportunity.
Market Pulse Summary
This announcement sharpened Prenetics’ capital allocation by ending new Bitcoin purchases and focusing cash and operational resources on IM8. The company reported over $70 million in cash, 510 BTC, zero debt, and IM8 reaching over $100 million ARR with FY2026 revenue projected at $180–$200 million. In context of prior balance-sheet moves and warrant restructuring, investors may watch IM8’s growth, margin trajectory, and any future financing steps tied to global expansion.
Key Terms
bitcoin financial
annualized recurring revenue financial
capital allocation financial
AI-generated analysis. Not financial advice.
Company’s Capital and Strategic Focus Now Exclusively Focused on IM8
IM8 FY 2026 Revenue Projected to Reach
CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, and parent of the IM8 premium health and longevity brand, today announced a strategic realignment to fully capitalize on the rapid growth of its consumer health brand, IM8. Prenetics ceased its daily Bitcoin purchasing activity as of December 4, 2025, and following approval by its Board of Directors, Prenetics announced that it will no longer pursue future acquisitions of Bitcoin. This decision allows Prenetics to dedicate its resources and attention exclusively to the significant market opportunity presented by IM8.
This strategic move comes at a time of unprecedented success in the consumer wellness sector with IM8, the fastest-growing supplement brand in industry history, which achieved over
Danny Yeung, CEO and Co-Founder of Prenetics, commented, "The phenomenal success of IM8 has exceeded all expectations and scaled much faster than our original expectations. Our Board and management team unanimously agreed that the most promising path to creating significant, sustainable shareholder value is to devote our undivided attention to this once-in-a-generation opportunity clearly visible in IM8. We are incredibly excited about the future of IM8 and are confident that by focusing our efforts, we can propel its growth to even greater heights. Operating from a position of strength, we are making disciplined strategic decisions that reflect our experience as operators and our commitment to maximizing long-term shareholder value."
The Company retains a robust financial position, with a strong balance sheet that includes over
Following Board approval, Prenetics will maintain its existing Bitcoin holdings of 510 BTC as a treasury reserve asset. Prenetics has committed to not allocate any existing capital or new capital for the purpose of acquiring additional Bitcoin. Capital allocation will be directed exclusively toward the growth, operations, and strategic expansion of IM8, including product innovation, brand building, talent acquisition, working capital, and international expansion.
Prenetics believes this decision strengthens strategic clarity, reinforces disciplined governance, and aligns the Company fully with shareholder priorities as it continues to scale IM8 globally.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
Investor Relations Contact
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: future alpha-generating activities involving the Company’s Bitcoin holdings could expose it to additional risks; the Company’s purchase of Bitcoin subjects it to risks related to extreme volatility and speculative nature of Bitcoin; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
FAQ
When did Prenetics stop buying Bitcoin and what is its current BTC holding (PRE)?
What FY2026 revenue does Prenetics project for IM8 (PRE)?
How large is IM8's recurring revenue run rate reported by Prenetics (PRE)?
What is Prenetics' reported cash and debt position after the capital shift (PRE)?
How will Prenetics allocate capital after ending Bitcoin purchases (PRE)?
Will Prenetics sell its existing Bitcoin holdings after the strategy change (PRE)?
